Literature DB >> 16774927

GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5.

Chang-Wook Lee1, Richard Rivera, Shannon Gardell, Adrienne E Dubin, Jerold Chun.   

Abstract

The signaling effects of lysophospholipids such as lysophosphatidic acid (LPA) are mediated by G protein-coupled receptors (GPCRs). There are currently four LPA receptors known as LPA(1-4). Genetic deletion studies have identified essential biological functions for LPA receptors in mice. However, these studies have also revealed phenotypes consistent with the existence of as yet unidentified receptors. Toward identifying new LPA receptors, we have screened collections of GPCR cDNAs using reverse transfection and cell-based assays. Here we report an interim result of one screen to identify receptors that produced LPA-dependent changes in cell shape: the orphan receptor GPR92 has properties of a new LPA receptor. Sequence analyses of human GPR92 and its mouse homolog have approximately 35% amino acid identity with LPA4/GPR23. The same cell-based approaches that were used to identify and/or characterize LPA(1-4), particularly heterologous expression in B103 cells or RH7777 cells, were utilized and compared with known LPA receptors. Retroviral-mediated expression of epitope-tagged receptors was further combined with G protein minigenes and pharmacological intervention, along with calcium imaging and whole-cell patch clamp electrophysiology. LPA-dependent receptor internalization following exposure to LPA but not related lysophospholipids was observed. Furthermore, LPA induced concentration-dependent activation of G(12/13) and G(q) and increased cAMP levels. Specific [3H]LPA binding was detected in cell membranes heterologously expressing GPR92 but not control membranes. Northern blot and reverse transcriptase-PCR studies indicated a broad low level of expression in many tissues including embryonic brain and enrichment in small intestine and sensory dorsal root ganglia, as well as embryonic stem cells. These results support GPR92 as a fifth LPA receptor, LPA5, which likely has distinct physiological functions in view of its expression pattern.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774927     DOI: 10.1074/jbc.M603670200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  154 in total

1.  Stimulatory actions of lysophosphatidic acid on mouse ATDC5 chondroprogenitor cells.

Authors:  Ryota Itoh; Shigenori Miura; Aki Takimoto; Shunya Kondo; Hiroko Sano; Yuji Hiraki
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

2.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 3.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 4.  Nutrient regulation of enteroendocrine cellular activity linked to cholecystokinin gene expression and secretion.

Authors:  K N Nilaweera; L Giblin; R P Ross
Journal:  J Physiol Biochem       Date:  2010-05-04       Impact factor: 4.158

5.  Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis.

Authors:  Adrienne E Dubin; Deron R Herr; Jerold Chun
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 6.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 7.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 8.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 9.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

10.  Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology.

Authors:  Whitney S McDonald; Elizabeth E Jones; Jonathan M Wojciak; Richard R Drake; Roger A Sabbadini; Neil G Harris
Journal:  Am J Pathol       Date:  2018-07-16       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.